DNA methyltransferase 3B expression is associated with poor outcome of stage I testicular seminoma

Eri Arai, Tohru Nakagawa, Saori Wakai-Ushijima, Hiroyuki Fujimoto, Yae Kanai

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aims: To examine in testicular seminomas the expression of DNA methyltransferase 3B (DNMT3B), which is known to be associated with early embryonic development and carcinogenesis, and to obtain a predictive marker for relapse of stage I seminomas. Methods and results: Immunohistochemical examination of DNMT3B was performed in 88 cases of seminoma, 35 (39.8%) of which showed widely scattered nuclear immunoreactivity for DNMT3B, and 53 (60.2%) of which were completely negative. The incidence of focal DNMT3B expression was higher in stage III seminomas (5/5, 100%) than in stage I (25/70, 35.7%) or stage II (5/13, 38.5%) seminomas (P=0.011). In stage I seminomas there were no significant correlations between DNMT3B expression and tumour size, invasion of the rete testis, or lymphatic or vascular involvement. Six of 25 cases (24%) showing DNMT3B expression relapsed, whereas only 3/45 cases (6.7%) lacking such expression did so (P=0.037). Patients with seminomas showing DNMT3B expression had a significantly lower relapse-free survival rate than patients whose tumours lacked this feature (P=0.0464). Conclusions: Patients with seminomas showing focal DNMT3B expression are at increased risk of relapse, and should be followed up carefully.

Original languageEnglish
JournalHistopathology
Volume60
Issue number6 B
DOIs
Publication statusPublished - 2012 May
Externally publishedYes

Fingerprint

Seminoma
Recurrence
Rete Testis
DNA methyltransferase 3B
Embryonic Development
Blood Vessels
Neoplasms
Carcinogenesis
Survival Rate
Incidence

Keywords

  • DNA methyltransferase 3B
  • Prognostication
  • Seminoma
  • Testicular germ cell tumour
  • Tumour relapse

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

DNA methyltransferase 3B expression is associated with poor outcome of stage I testicular seminoma. / Arai, Eri; Nakagawa, Tohru; Wakai-Ushijima, Saori; Fujimoto, Hiroyuki; Kanai, Yae.

In: Histopathology, Vol. 60, No. 6 B, 05.2012.

Research output: Contribution to journalArticle

Arai, Eri ; Nakagawa, Tohru ; Wakai-Ushijima, Saori ; Fujimoto, Hiroyuki ; Kanai, Yae. / DNA methyltransferase 3B expression is associated with poor outcome of stage I testicular seminoma. In: Histopathology. 2012 ; Vol. 60, No. 6 B.
@article{84e373218f56469fab03214cda869991,
title = "DNA methyltransferase 3B expression is associated with poor outcome of stage I testicular seminoma",
abstract = "Aims: To examine in testicular seminomas the expression of DNA methyltransferase 3B (DNMT3B), which is known to be associated with early embryonic development and carcinogenesis, and to obtain a predictive marker for relapse of stage I seminomas. Methods and results: Immunohistochemical examination of DNMT3B was performed in 88 cases of seminoma, 35 (39.8{\%}) of which showed widely scattered nuclear immunoreactivity for DNMT3B, and 53 (60.2{\%}) of which were completely negative. The incidence of focal DNMT3B expression was higher in stage III seminomas (5/5, 100{\%}) than in stage I (25/70, 35.7{\%}) or stage II (5/13, 38.5{\%}) seminomas (P=0.011). In stage I seminomas there were no significant correlations between DNMT3B expression and tumour size, invasion of the rete testis, or lymphatic or vascular involvement. Six of 25 cases (24{\%}) showing DNMT3B expression relapsed, whereas only 3/45 cases (6.7{\%}) lacking such expression did so (P=0.037). Patients with seminomas showing DNMT3B expression had a significantly lower relapse-free survival rate than patients whose tumours lacked this feature (P=0.0464). Conclusions: Patients with seminomas showing focal DNMT3B expression are at increased risk of relapse, and should be followed up carefully.",
keywords = "DNA methyltransferase 3B, Prognostication, Seminoma, Testicular germ cell tumour, Tumour relapse",
author = "Eri Arai and Tohru Nakagawa and Saori Wakai-Ushijima and Hiroyuki Fujimoto and Yae Kanai",
year = "2012",
month = "5",
doi = "10.1111/j.1365-2559.2012.04174.x",
language = "English",
volume = "60",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "6 B",

}

TY - JOUR

T1 - DNA methyltransferase 3B expression is associated with poor outcome of stage I testicular seminoma

AU - Arai, Eri

AU - Nakagawa, Tohru

AU - Wakai-Ushijima, Saori

AU - Fujimoto, Hiroyuki

AU - Kanai, Yae

PY - 2012/5

Y1 - 2012/5

N2 - Aims: To examine in testicular seminomas the expression of DNA methyltransferase 3B (DNMT3B), which is known to be associated with early embryonic development and carcinogenesis, and to obtain a predictive marker for relapse of stage I seminomas. Methods and results: Immunohistochemical examination of DNMT3B was performed in 88 cases of seminoma, 35 (39.8%) of which showed widely scattered nuclear immunoreactivity for DNMT3B, and 53 (60.2%) of which were completely negative. The incidence of focal DNMT3B expression was higher in stage III seminomas (5/5, 100%) than in stage I (25/70, 35.7%) or stage II (5/13, 38.5%) seminomas (P=0.011). In stage I seminomas there were no significant correlations between DNMT3B expression and tumour size, invasion of the rete testis, or lymphatic or vascular involvement. Six of 25 cases (24%) showing DNMT3B expression relapsed, whereas only 3/45 cases (6.7%) lacking such expression did so (P=0.037). Patients with seminomas showing DNMT3B expression had a significantly lower relapse-free survival rate than patients whose tumours lacked this feature (P=0.0464). Conclusions: Patients with seminomas showing focal DNMT3B expression are at increased risk of relapse, and should be followed up carefully.

AB - Aims: To examine in testicular seminomas the expression of DNA methyltransferase 3B (DNMT3B), which is known to be associated with early embryonic development and carcinogenesis, and to obtain a predictive marker for relapse of stage I seminomas. Methods and results: Immunohistochemical examination of DNMT3B was performed in 88 cases of seminoma, 35 (39.8%) of which showed widely scattered nuclear immunoreactivity for DNMT3B, and 53 (60.2%) of which were completely negative. The incidence of focal DNMT3B expression was higher in stage III seminomas (5/5, 100%) than in stage I (25/70, 35.7%) or stage II (5/13, 38.5%) seminomas (P=0.011). In stage I seminomas there were no significant correlations between DNMT3B expression and tumour size, invasion of the rete testis, or lymphatic or vascular involvement. Six of 25 cases (24%) showing DNMT3B expression relapsed, whereas only 3/45 cases (6.7%) lacking such expression did so (P=0.037). Patients with seminomas showing DNMT3B expression had a significantly lower relapse-free survival rate than patients whose tumours lacked this feature (P=0.0464). Conclusions: Patients with seminomas showing focal DNMT3B expression are at increased risk of relapse, and should be followed up carefully.

KW - DNA methyltransferase 3B

KW - Prognostication

KW - Seminoma

KW - Testicular germ cell tumour

KW - Tumour relapse

UR - http://www.scopus.com/inward/record.url?scp=84860342922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860342922&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2012.04174.x

DO - 10.1111/j.1365-2559.2012.04174.x

M3 - Article

C2 - 22394436

AN - SCOPUS:84860342922

VL - 60

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 6 B

ER -